Former UK prime minister Rishi Sunak has proposed a targeted prostate cancer screening programme for men at higher risk, rekindling a national discussion on how to save lives and address health inequalities. The plan, supported by Prostate Cancer Research, would provide regular screening for men aged 45 to 69, with emphasis on those of African-Caribbean descent or with a family history of the disease.
The case for targeted screening
Prostate cancer is the most common cancer among UK men, with about 63,000 new cases each year. However, disparities persist in who is diagnosed, how early it is detected, and survival outcomes, reflecting variations in race, region, and access to care. African-Caribbean men face a higher incidence and mortality risk, and a family history further elevates risk. These differences are not solely biological; they also stem from gaps in awareness, access to care, and trust in the health system. A targeted program could begin to reduce these gaps.
The proposed screening pathway would start with a prostate-specific antigen (PSA) test to measure the concentration of a protein produced by the prostate. If PSA levels exceed a defined threshold, follow-up steps would include MRI to improve diagnostic accuracy and, when necessary, a biopsy to confirm cancer. Advances in imaging over the past decade enhance the ability to distinguish aggressive cancers from indolent ones, increasing the precision of modern screening compared with ten years ago.
Early detection is crucial in prostate cancer, which often develops without symptoms for years. Detecting cancer earlier through targeted screening could enable less invasive and more effective treatment, improving the chances of cure or long-term control. The model emphasizes inclusivity in men’s health, recognizing that African-Caribbean men and those in deprived areas are underrepresented in research and may face barriers to care. A scientifically grounded, community-engaged screening program could promote trust, participation, and equity, and may stimulate biobank research to understand ethnic and genetic risk better. It could also set a precedent for equity-driven preventive health in men.
supporters estimate the programme would cost about £25 million annually (roughly £18 per participant), arguing it would be less expensive than many national screening initiatives while offering potentially transformative benefits. Regional disparities persist, with Scotland, the north-west, West Midlands, and Wales showing lower survival rates, highlighting geographic inequities in prognosis. Beyond early diagnosis, the proposal aims to foster participation among underrepresented groups and stimulate broader preventive health engagement.
The case against widespread PSA screening
Critics argue that men should engage regularly with healthcare providers to manage health risks and detect conditions early. While PSA testing is simple, its reliability is limited. At the conventional PSA threshold of 4 ng/mL, the test’s sensitivity is around 20%, meaning many cancers may be missed, while false positives can trigger invasive and stressful diagnostic cascades. Prostate infections, recent exercise, or benign enlargement can elevate PSA, leading to unnecessary follow-up procedures and anxiety.
Moreover, a portion of detected cancers are slow-growing and may not impact a man’s lifespan. Overtreatment can cause significant side effects, including urinary incontinence and erectile dysfunction, as well as psychological distress. These harms can arise from both the cancer itself and subsequent interventions. Some cancers identified by PSA screening may never become life-threatening, raising concerns about net benefit in a population-level screening program.
From a health-system perspective, implementing a national PSA screening program would demand substantial resources—more testing, imaging, and specialist consultations—potentially diverting capacity from other needs. Estimates suggest the approach could increase testing volume and associated workloads by about 23%, posing a challenge to an already stretched NHS. Until a test can reliably distinguish life-threatening cancers from indolent ones, proponents caution that a nationwide screening program might cause more harm than good, reclassifying healthy individuals as patients and straining services without delivering clear, proportional benefits.
Ultimately, the debate centers on the balance between potential lives saved and harms from false positives, overdiagnosis, and overtreatment. A cautious path emphasizes better risk stratification, improved testing accuracy, and targeted outreach to underserved populations, while avoiding broad, population-wide screening until optimal tools and evidence are available.
Related topics
